CD47 and neoplasm: Strategies that target CD47, including the use of the anti-CD47 antibody [29] and CD47 knockdown [30] for cancer therapy, demonstrated that CD47 blockade significantly increased macrophage infiltration and phagocytosis, thereby enhancing the anti-tumor response.